GWPH 72.43
GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex(R) in the Treatment of Lennox-Gastaut Syndrome
GlobeNewswire - Fri Feb 28, 7:00AM CST
GW Pharmaceuticals plc (AIM:GWP) (Nasdaq:GWPH) ("GW") announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Epidiolex(R), GW's product candidate that contains plant-derived Cannabidiol (CBD) as its active ingredient, for use in treating children with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. Epidiolex is an oral liquid formulation of a highly purified extract of CBD, a non-psychoactive molecule from the cannabis plant.
GW Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 26, 4:00PM CST
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Cowen and Company 34th Annual Health Care Conference on Monday, 3 March, 2014 at 3:30 p.m. ET. The conference will be held at the Boston Marriott Copley Place.
Cannabis Sector's High Volume Trading Report - Company Enters Into Agreement with a Colorado Marijuana Facility Developer
PR Newswire - Wed Feb 26, 7:50AM CST
Cannabis pioneers make advancements as sector continues to attract growing investor interest: DirectView Holdings, Inc. (OTC: DIRV), Growlife, Inc. (OTCBB: PHOT), GW Pharmaceuticals plc (NASDAQ: GWPH), Hemp, Inc. (OTC: HEMP) and Dewmar International BMC, Inc. (OTC: DEWM).
The 1 Legal Way You Could Get Rich From Marijuana
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 22, 9:50AM CST
Times are certainly changing when it comes to the public's perception of marijuana usage. It all began 16 years ago, when medical marijuana was allowed to be purchased in its first U.S. state. Now, there are 20 states, plus the District of...
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Feb 22, 7:38AM CST
It's always fun watching the best of the best compete in the Winter Olympic games. But, of course, not everyone can win. Plenty of athletes experience the proverbial agony of defeat. That's the case with investing, too. Not every stock can be a...
Cannabis Sector Briefing: Company Launches Natural Resource Development Program for Marijuana & Hemp Products
PR Newswire - Thu Feb 20, 9:16AM CST
Healthcare Market updates and Medical Marijuana sector news & developments: PetroTech Oil and Gas Inc. (OTC: PTOG), GW Pharmaceuticals plc, (NASDAQ: GWPH), Medical Marijuana, Inc. (OTC: MJNA), Dehaier Medical Systems Ltd. (NASDAQ: DHRM) and Hemp, Inc. (OTC: HEMP)
Medical Marijuana Explosion Continues as Company Agrees to Purchase 83,000 S/F Complex in AZ
PR Newswire - Wed Feb 19, 7:50AM CST
Alternative care industry sees growth as medical marijuana companies continue expansion: Zoned Properties, Inc. (OTC: ZDPY), Growlife, Inc. (OTCBB: PHOT), Advanced Cannabis Solutions, Inc. (OTCBB: CANN) Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) and GW Pharmaceuticals plc (NASDAQ: GWPH)
Canaccord Fumes Over Pot Deal
at The Street - Fri Feb 14, 10:39AM CST
The Toronto-based wealth management and securities company helped aspiring pot grower Enertopia raise over a million dollars but, upon being informed by TheStreet that it had been credited in a regulatory filing, Canaccord wasn't feeling the vibes.
Marijuana Stocks: A Real Investing Opportunity or Not Worth the Hype?
Max Macaluso, The Motley Fool - Motley Fool - Thu Feb 13, 12:45PM CST
According to an oft-cited report by ArcView Market Research, the legal marijuana market may top $2.3 billion in sales this year. Investors have undoubtedly been keeping a close eye on this market, but note that this is the potential size of the...
GW Pharmaceuticals to Present at the Leerink Global Healthcare Conference
GlobeNewswire - Mon Feb 10, 11:00AM CST
GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Dr. Stephen Wright, GW's Director of Research and Development, is scheduled to present at the Leerink Global Healthcare Conference on Wednesday, 12 February, 2014 at 3:30 p.m. ET. The conference will be held at the Waldorf Astoria Hotel in New York City.
5 Biotech Stocks Spiking on Unusual Volume
at The Street - Mon Feb 10, 7:42AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Jim Cramer's 6 Stocks in 60 Seconds: DIN SBUX RHT ATHN LULU GWPH
at The Street - Fri Feb 07, 4:06PM CST
Cramer agrees with the analyst calls on DineEquity and Starbucks and calls GW Pharmaceuticals the most legitimate marijuana stock.
Biotech Losers: InterMune, Enanta, and GW Pharmaceuticals
David Williamson and Max Macaluso, The Motley Fool - Motley Fool - Thu Feb 06, 7:45PM CST
In this video from Thursday's Market Checkup , Motley Fool health-care analysts David Williamson and Max Macaluso dive into the biggest stories impacting health-care investors on the market today. In this segment, a look at the biotech losers on...
GW Pharmaceuticals plc (GWPH) Jumps: Stock Rises 7.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 8:18AM CST
GW Pharmaceuticals plc (GWPH) was a big mover last session, as the company saw its shares rise by roughly 8% on the day.
Medical Marijuana Industry Continues Rapid Expansion As Leaders Acquire New Dispensary Sites
PR Newswire - Wed Feb 05, 8:02AM CST
Alternative care pioneers continue to grow market with increasing demand: Zoned Properties[SM], Inc. (OTC: ZDPY), GW Pharmaceuticals plc (NASDAQ: GWPH), Growlife, Inc. (OTCBB: PHOT), Medbox, Inc. (OTC: MDBX) and Idenix Pharmaceuticals Inc. (NASDAQ: IDIX)
GW Pharmaceuticals plc Reports First Quarter 2014 Financial Results and Operational Progress
GlobeNewswire - Wed Feb 05, 12:59AM CST
-Recent Successful $101 Million Financing Accelerates Epidiolex Development
Can GW Pharma (GWPH) Continue to Rise? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 04, 5:36AM CST
Can GW Pharma (GWPH) Continue to Rise?
GW Pharmaceuticals to Report Q1 2014 Financial Results and Host Conference Call on 5 February, 2014
GlobeNewswire - Wed Jan 29, 1:00AM CST
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 February, 2014 its first quarter financial results for the period ending 31 December, 2013. GW will also host a conference call the same day at 1:00 p.m. GMT (8:00 a.m. EST).
GW Pharmaceuticals plc Announces the Closing of Its U.S. Follow-on Offering of American Depositary Shares (ADSs) on the NASDAQ Global Market and Full Exercise of Underwriters' Option to Purchase Additional ADSs
GlobeNewswire - Tue Jan 14, 10:18AM CST
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of its previously announced follow-on offering on the NASDAQ Global Market of 2,441,110 American Depositary Shares (ADSs) and the full exercise by the underwriters of their option to purchase 366,165 additional ADSs at a price of $36.00 per ADS raising gross proceeds of $101.1 million (before deducting underwriting discount, commissions and offering expenses).
Keep An Eye on Pfizer Inc., GW Pharmaceuticals PLC - ADR, and VIVUS Inc. Today
Leo Sun, The Motley Fool - Motley Fool - Tue Jan 14, 7:51AM CST
Follow @leokornsun // full story)
GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex(R) in the Treatment of Lennox-Gastaut Syndrome
GlobeNewswire - Fri Feb 28, 7:00AM CST
GW Pharmaceuticals plc (AIM:GWP) (Nasdaq:GWPH) ("GW") announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Epidiolex(R), GW's product candidate that contains plant-derived Cannabidiol (CBD) as its active ingredient, for use in treating children with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. Epidiolex is an oral liquid formulation of a highly purified extract of CBD, a non-psychoactive molecule from the cannabis plant.
GW Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 26, 4:00PM CST
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Cowen and Company 34th Annual Health Care Conference on Monday, 3 March, 2014 at 3:30 p.m. ET. The conference will be held at the Boston Marriott Copley Place.
Cannabis Sector's High Volume Trading Report - Company Enters Into Agreement with a Colorado Marijuana Facility Developer
PR Newswire - Wed Feb 26, 7:50AM CST
Cannabis pioneers make advancements as sector continues to attract growing investor interest: DirectView Holdings, Inc. (OTC: DIRV), Growlife, Inc. (OTCBB: PHOT), GW Pharmaceuticals plc (NASDAQ: GWPH), Hemp, Inc. (OTC: HEMP) and Dewmar International BMC, Inc. (OTC: DEWM).
The 1 Legal Way You Could Get Rich From Marijuana
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 22, 9:50AM CST
Times are certainly changing when it comes to the public's perception of marijuana usage. It all began 16 years ago, when medical marijuana was allowed to be purchased in its first U.S. state. Now, there are 20 states, plus the District of...
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Feb 22, 7:38AM CST
It's always fun watching the best of the best compete in the Winter Olympic games. But, of course, not everyone can win. Plenty of athletes experience the proverbial agony of defeat. That's the case with investing, too. Not every stock can be a...
Cannabis Sector Briefing: Company Launches Natural Resource Development Program for Marijuana & Hemp Products
PR Newswire - Thu Feb 20, 9:16AM CST
Healthcare Market updates and Medical Marijuana sector news & developments: PetroTech Oil and Gas Inc. (OTC: PTOG), GW Pharmaceuticals plc, (NASDAQ: GWPH), Medical Marijuana, Inc. (OTC: MJNA), Dehaier Medical Systems Ltd. (NASDAQ: DHRM) and Hemp, Inc. (OTC: HEMP)
Medical Marijuana Explosion Continues as Company Agrees to Purchase 83,000 S/F Complex in AZ
PR Newswire - Wed Feb 19, 7:50AM CST
Alternative care industry sees growth as medical marijuana companies continue expansion: Zoned Properties, Inc. (OTC: ZDPY), Growlife, Inc. (OTCBB: PHOT), Advanced Cannabis Solutions, Inc. (OTCBB: CANN) Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) and GW Pharmaceuticals plc (NASDAQ: GWPH)
Canaccord Fumes Over Pot Deal
at The Street - Fri Feb 14, 10:39AM CST
The Toronto-based wealth management and securities company helped aspiring pot grower Enertopia raise over a million dollars but, upon being informed by TheStreet that it had been credited in a regulatory filing, Canaccord wasn't feeling the vibes.
Marijuana Stocks: A Real Investing Opportunity or Not Worth the Hype?
Max Macaluso, The Motley Fool - Motley Fool - Thu Feb 13, 12:45PM CST
According to an oft-cited report by ArcView Market Research, the legal marijuana market may top $2.3 billion in sales this year. Investors have undoubtedly been keeping a close eye on this market, but note that this is the potential size of the...
GW Pharmaceuticals to Present at the Leerink Global Healthcare Conference
GlobeNewswire - Mon Feb 10, 11:00AM CST
GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Dr. Stephen Wright, GW's Director of Research and Development, is scheduled to present at the Leerink Global Healthcare Conference on Wednesday, 12 February, 2014 at 3:30 p.m. ET. The conference will be held at the Waldorf Astoria Hotel in New York City.
5 Biotech Stocks Spiking on Unusual Volume
at The Street - Mon Feb 10, 7:42AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Jim Cramer's 6 Stocks in 60 Seconds: DIN SBUX RHT ATHN LULU GWPH
at The Street - Fri Feb 07, 4:06PM CST
Cramer agrees with the analyst calls on DineEquity and Starbucks and calls GW Pharmaceuticals the most legitimate marijuana stock.
Biotech Losers: InterMune, Enanta, and GW Pharmaceuticals
David Williamson and Max Macaluso, The Motley Fool - Motley Fool - Thu Feb 06, 7:45PM CST
In this video from Thursday's Market Checkup , Motley Fool health-care analysts David Williamson and Max Macaluso dive into the biggest stories impacting health-care investors on the market today. In this segment, a look at the biotech losers on...
GW Pharmaceuticals plc (GWPH) Jumps: Stock Rises 7.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 8:18AM CST
GW Pharmaceuticals plc (GWPH) was a big mover last session, as the company saw its shares rise by roughly 8% on the day.
Medical Marijuana Industry Continues Rapid Expansion As Leaders Acquire New Dispensary Sites
PR Newswire - Wed Feb 05, 8:02AM CST
Alternative care pioneers continue to grow market with increasing demand: Zoned Properties[SM], Inc. (OTC: ZDPY), GW Pharmaceuticals plc (NASDAQ: GWPH), Growlife, Inc. (OTCBB: PHOT), Medbox, Inc. (OTC: MDBX) and Idenix Pharmaceuticals Inc. (NASDAQ: IDIX)
GW Pharmaceuticals plc Reports First Quarter 2014 Financial Results and Operational Progress
GlobeNewswire - Wed Feb 05, 12:59AM CST
-Recent Successful $101 Million Financing Accelerates Epidiolex Development
Can GW Pharma (GWPH) Continue to Rise? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 04, 5:36AM CST
Can GW Pharma (GWPH) Continue to Rise?
GW Pharmaceuticals to Report Q1 2014 Financial Results and Host Conference Call on 5 February, 2014
GlobeNewswire - Wed Jan 29, 1:00AM CST
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 February, 2014 its first quarter financial results for the period ending 31 December, 2013. GW will also host a conference call the same day at 1:00 p.m. GMT (8:00 a.m. EST).
GW Pharmaceuticals plc Announces the Closing of Its U.S. Follow-on Offering of American Depositary Shares (ADSs) on the NASDAQ Global Market and Full Exercise of Underwriters' Option to Purchase Additional ADSs
GlobeNewswire - Tue Jan 14, 10:18AM CST
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of its previously announced follow-on offering on the NASDAQ Global Market of 2,441,110 American Depositary Shares (ADSs) and the full exercise by the underwriters of their option to purchase 366,165 additional ADSs at a price of $36.00 per ADS raising gross proceeds of $101.1 million (before deducting underwriting discount, commissions and offering expenses).
Keep An Eye on Pfizer Inc., GW Pharmaceuticals PLC - ADR, and VIVUS Inc. Today
Leo Sun, The Motley Fool - Motley Fool - Tue Jan 14, 7:51AM CST
Follow @leokornsun // full story)
